IMRX Immuneering Corp
Price (delayed)
$1.56
Market cap
$55.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.04
Enterprise value
$24M
Highlights
The debt has declined by 7% year-on-year
The quick ratio has plunged by 56% YoY and by 34% from the previous quarter
Immuneering's equity has plunged by 54% YoY and by 28% from the previous quarter
Key stats
What are the main financial stats of IMRX
Market
Valuations
Earnings
Shares outstanding
35.89M
Market cap
$55.98M
Enterprise value
$24M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$64.07M
Net income
-$61.04M
EBIT
-$61.04M
EBITDA
-$60.32M
Free cash flow
-$55.08M
Per share
Balance sheet
Liquidity
EPS
-$2.04
EPS diluted
-$2.04
Free cash flow per share
-$1.84
Book value per share
$1.33
Revenue per share
$0
TBVPS
$1.52
Total assets
$52.71M
Total liabilities
$11.33M
Debt
$4.16M
Equity
$41.39M
Working capital
$32.08M
Debt to equity
0.1
Current ratio
5.28
Quick ratio
4.82
Net debt/EBITDA
0.53
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-85.3%
Return on equity
-100%
Return on invested capital
-588.5%
Return on capital employed
-135%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMRX stock price
How has the Immuneering stock price performed over time
Intraday
4%
1 week
-4.88%
1 month
-5.45%
1 year
-37.6%
YTD
-29.09%
QTD
2.63%
Financial performance
How have Immuneering's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$64.07M
Net income
-$61.04M
Gross margin
N/A
Net margin
N/A
The net income has declined by 14% year-on-year and by 5% since the previous quarter
The operating income has declined by 10% year-on-year and by 3.6% since the previous quarter
Growth
What is Immuneering's growth rate over time
Valuation
What is Immuneering stock price valuation
P/E
N/A
P/B
1.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 9% year-on-year and by 3.6% since the previous quarter
Immuneering's equity has plunged by 54% YoY and by 28% from the previous quarter
IMRX's P/B is 2.7% more than its last 4 quarters average of 1.1
Efficiency
How efficient is Immuneering business performance
IMRX's return on invested capital has dropped by 191% year-on-year and by 72% since the previous quarter
The ROE has plunged by 90% YoY and by 26% from the previous quarter
The ROA has dropped by 79% year-on-year and by 23% since the previous quarter
Dividends
What is IMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMRX.
Financial health
How did Immuneering financials performed over time
The quick ratio has plunged by 56% YoY and by 34% from the previous quarter
The current ratio has dropped by 53% year-on-year and by 34% since the previous quarter
The debt is 90% smaller than the equity
IMRX's debt to equity has surged by 100% year-on-year and by 43% since the previous quarter
Immuneering's equity has plunged by 54% YoY and by 28% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.